Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM035
MIFTS: 47

Pulmonary Eosinophilia

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Eosinophilia

About this section

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 56 15 74
Asthmatic Pulmonary Eosinophilia 74

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 36 518.3
MeSH 45 D011657
SNOMED-CT 69 91053000
ICD10 34 J82
Sources

Summaries for Pulmonary Eosinophilia

About this section
Disease Ontology : 12 A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to chronic eosinophilic pneumonia and ascaris lumbricoides infection, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Nitric Oxide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and skin, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic pneumonia 32.6 CCL11 CCL5 IL5 RNASE3
2 ascaris lumbricoides infection 32.0 IL13 IL5
3 eosinophilic pneumonia 31.3 CCL11 CCL17 CCL5 IL13 IL5 RNASE3
4 bronchitis 30.0 CCL11 IL5 RNASE3
5 filarial elephantiasis 29.9 IL4 IL5
6 eosinophilic granuloma 29.6 EPX RNASE3
7 hypereosinophilic syndrome 29.5 CCL11 CCL17 EPX IL13 IL4 IL5
8 folliculitis 29.4 CCL11 CCL5 IL4 IL5
9 pneumonia 29.2 CCL11 CCL5 IL13 IL5 SFTPD
10 aspergillosis 29.1 CCL17 IL4 IL5 SFTPD
11 interstitial lung disease 29.0 CCL17 CCL5 IL4 SFTPD
12 lung disease 28.9 CCL5 IL13 IL5 PDE4A RNASE3 SFTPD
13 bronchiolitis 28.8 CCL11 CCL5 IL13 IL4 IL5 RNASE3
14 allergic bronchopulmonary aspergillosis 28.4 CCL17 EPX IL4 IL5 SFTPD
15 asthma 28.1 CCL11 CCL17 CCL5 EPX IL13 IL4
16 allergic asthma 27.9 CCL11 CCL17 CCL5 EPX IL13 IL4
17 loeffler syndrome 12.1
18 loeffler endocarditis 10.3 IL5 RNASE3
19 idiopathic acute eosinophilic pneumonia 10.3
20 pemphigoid gestationis 10.3 CCL11 IL5
21 cow milk allergy 10.3 IL5 RNASE3
22 chronic meningitis 10.3 CCL11 IL5
23 sinusitis 10.3 IL5 RNASE3
24 papillary conjunctivitis 10.3 CCL11 IL4
25 vulvovaginitis 10.3 CCL11 CCL5
26 maxillary sinusitis 10.3 CCL5 RNASE3
27 cytokine deficiency 10.3 IL13 IL5
28 scleritis 10.3 IL4 IL5
29 egg allergy 10.3 IL4 IL5
30 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL13 IL5
31 sulfamethoxazole allergy 10.3 IL4 IL5
32 trichinosis 10.2 IL4 IL5
33 gaucher disease, type ii 10.2 IL4 IL5
34 non-suppurative otitis media 10.2 IL4 IL5
35 toxic oil syndrome 10.2 IL4 IL5
36 african tick-bite fever 10.2 CCL5 IL13
37 inclusion conjunctivitis 10.2 CCL5 IL5
38 wells syndrome 10.2 IL5 RNASE3
39 penicillin allergy 10.2 IL13 IL4
40 vasculogenic impotence 10.2 PDE4A RNASE3
41 orofacial granulomatosis 10.2 CCL5 IL4
42 beta-lactam allergy 10.1 IL13 IL4
43 necatoriasis 10.1 CCL17 IL5
44 bullous skin disease 10.1 CCL5 IL5
45 status asthmaticus 10.1 CCL5 IL5 RNASE3
46 bullous pemphigoid 10.1 CCL11 IL5 RNASE3
47 cough variant asthma 10.1 IL4 IL5 RNASE3
48 atopic keratoconjunctivitis 10.1 IL4 IL5 RNASE3
49 intrinsic asthma 10.1 IL4 IL5 RNASE3
50 cellulitis 10.1 IL5 RNASE3

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Ischemic Heart Disease
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia
Sources

Symptoms & Phenotypes for Pulmonary Eosinophilia

About this section

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CCL11 CCL17 CCL5 EPX IL13 IL4
2 immune system MP:0005387 9.61 CCL11 CCL17 CCL5 EPX IL13 IL4
3 respiratory system MP:0005388 9.02 CCL11 IL13 IL4 IL5 SFTPD
Sources

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
6
Omalizumab Approved, Investigational Phase 4,Phase 2 242138-07-4
7
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
9 Reslizumab Approved, Investigational Phase 4,Phase 3,Phase 2
10
Budesonide Approved Phase 4 51333-22-3 5281004 63006
11 Benralizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1044511-01-4
12
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
13 Hormone Antagonists Phase 4,Phase 2,Phase 3
14 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
15 Prednisolone acetate Phase 4,Phase 3
16 Neuroprotective Agents Phase 4
17 glucocorticoids Phase 4,Phase 2,Phase 3
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
19 Peripheral Nervous System Agents Phase 4,Phase 2
20 Antiemetics Phase 4
21 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
22 Gastrointestinal Agents Phase 4
23 Protective Agents Phase 4
24 Methylprednisolone Acetate Phase 4,Phase 3
25 Hormones Phase 4,Phase 2,Phase 3
26 Autonomic Agents Phase 4,Phase 2
27 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
28 Immunologic Factors Phase 4,Phase 2,Phase 3
29 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
30 Tocolytic Agents Phase 4,Phase 2
31 Adrenergic Agents Phase 4,Phase 2
32 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Not Applicable
33 Adrenergic beta-Agonists Phase 4,Phase 2
34 Adrenergic Agonists Phase 4,Phase 2
35 Bronchodilator Agents Phase 4,Phase 2
36 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Neurotransmitter Agents Phase 4,Phase 2
38 Anti-Allergic Agents Phase 4,Phase 2
39 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
41 Albuterol Phase 4,Phase 2
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
43 Radiopharmaceuticals Phase 4
44 Fluorodeoxyglucose F18 Phase 4
45
Sodium Citrate Approved, Investigational Phase 3 68-04-2
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
47 Immunoglobulin G Phase 3
48 Antineoplastic Agents, Immunological Phase 2, Phase 3
49 Citrate Phase 3
50
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
3 Small Particle Steroids in Refractory Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
4 Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma Recruiting NCT03610685 Phase 4 Prednisolone;Placebo oral capsule
5 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Recruiting NCT03034005 Phase 4 Budesonide
6 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
7 Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatic (CHINOOK) Not yet recruiting NCT03953300 Phase 4
8 An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation Terminated NCT02937168 Phase 4 Reslizumab;Fludeoxyglucose F 18 (FDG);Placebo
9 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
10 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
11 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
12 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
13 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
14 Study of Mepolizumab Autoinjector in Asthmatics Completed NCT03099096 Phase 3 Mepolizumab
15 Study of Mepolizumab Safety Syringe in Asthmatics Completed NCT03021304 Phase 3 Mepolizumab
16 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
17 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Completed NCT02135692 Phase 3 SOC
18 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
19 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
20 Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Recruiting NCT03557307 Phase 3
21 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Active, not recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
22 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
23 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
24 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
25 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
26 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
27 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
28 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Completed NCT02560610 Phase 2 OC000459;Placebo
29 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Completed NCT02377427 Phase 2 Mepolizumab
30 Effect of Benralizumab in Atopic Dermatitis Recruiting NCT03563066 Phase 2 Benralizumab;Placebo Control
31 Pregnancy Rate, Asthma, Infertility, Omalizumab Recruiting NCT03727971 Phase 2 Omalizumab Injection;NaCl
32 GB001 in Adult Subjects With Moderate to Severe Asthma Recruiting NCT03683576 Phase 2 GB001;Placebo Oral Tablet
33 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia Unknown status NCT01152424
34 Intense Airway Eosinophilia in Asthma Completed NCT03696914
35 Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma Completed NCT03453021 Mepolizumab
36 Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center Completed NCT03209934
37 Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
38 A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
39 Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Recruiting NCT03733535 Not Applicable Benralizumab;129 Xenon
40 Exploring Asthma Exacerbations in Mepolizumab Treated Patients Recruiting NCT03324230
41 BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS) Recruiting NCT03925415
42 Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab Recruiting NCT03369574 Reslizumab
43 European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Recruiting NCT02852928
44 Real-world Daptomycin Use in Chinese ICUs Recruiting NCT03588637
45 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
46 Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma Active, not recruiting NCT03563521
47 Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland Not yet recruiting NCT03907137
48 Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients Not yet recruiting NCT03931954

Search NIH Clinical Center for Pulmonary Eosinophilia

Sources

Genetic Tests for Pulmonary Eosinophilia

About this section
Sources

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

42
Bone, T Cells, Skin, Heart, Testes, Bone Marrow, Lung
Sources

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 302)
# Title Authors Year
1
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. ( 29969926 )
2019
2
Filarial tropical pulmonary eosinophilia. ( 30720371 )
2019
3
Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. ( 28488945 )
2018
4
The Rare Complication and Diagnostic Challenges of Pulmonary Eosinophilia in Graft versus Host Disease Patients after Hematopoietic Stem Cell Transplantation. ( 29058073 )
2017
5
Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. ( 28454572 )
2017
6
Pulmonary Eosinophilia From Inhaled Colistin. ( 28065254 )
2017
7
Tropical pulmonary eosinophilia: effect of addition of corticosteroids after failure of diethylcarbamazine therapy. ( 28198995 )
2017
8
In vivo neutralization of α4 and β7 integrins inhibits eosinophil trafficking and prevents lung injury during tropical pulmonary eosinophilia in mice. ( 28736941 )
2017
9
A rare presentation of hydropneumothorax in tropical pulmonary eosinophilia: cavitation and pneumonic consolidation in a child. ( 26376823 )
2016
10
Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. ( 26489428 )
2016
11
Concurrent sensitization to Aspergillus Fumigatus in tropical pulmonary eosinophilia. ( 27374215 )
2016
12
Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. ( 27445539 )
2016
13
Pulmonary eosinophilia associated to treatment with natalizumab. ( 27512514 )
2016
14
Simple pulmonary eosinophilia associated with clozapine treatment. ( 25514065 )
2015
15
Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. ( 26044350 )
2015
16
An Unusual Case of Foreign Body Aspiration Masquerading as Pulmonary Eosinophilia. ( 26266154 )
2015
17
Simple pulmonary eosinophilia found on follow-up computed tomography of oncologic patients. ( 25082475 )
2014
18
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. ( 23926350 )
2013
19
Pulmonary eosinophilia caused by testosterone cypionate. ( 23998379 )
2013
20
Tropical pulmonary eosinophilia--a review. ( 24135173 )
2013
21
A rare case of ethambutol induced pulmonary eosinophilia. ( 24250213 )
2013
22
FICZ, a tryptophan photoproduct, suppresses pulmonary eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-induced allergic asthma. ( 22561122 )
2012
23
Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. ( 22172479 )
2012
24
Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. ( 22252873 )
2012
25
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. ( 22331917 )
2012
26
Acquired alpha 1-antitrypsin deficiency in tropical pulmonary eosinophilia. ( 21808138 )
2011
27
Role of oxidants in interstitial lung diseases: pneumoconioses, constrictive bronchiolitis, and chronic tropical pulmonary eosinophilia. ( 22131646 )
2011
28
A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. ( 21160052 )
2011
29
Regulator of calcineurin 1 (Rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice. ( 21741935 )
2011
30
Chlorogenic acid suppresses pulmonary eosinophilia, IgE production, and Th2-type cytokine production in an ovalbumin-induced allergic asthma: activation of STAT-6 and JNK is inhibited by chlorogenic acid. ( 20637839 )
2010
31
Serum C3d levels in tropical pulmonary eosinophilia. ( 20424307 )
2010
32
Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. ( 20719375 )
2010
33
Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study. ( 21092270 )
2010
34
Enhancement of ovalbumin-induced pulmonary eosinophilia by intranasal administration of alpha1-proteinase inhibitor type 2 antisense oligonucleotides. ( 19111575 )
2009
35
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. ( 19594395 )
2009
36
Pulmonary eosinophilia. ( 19618037 )
2009
37
A carbohydrate fraction, AIP1 from Artemisia iwayomogi suppresses pulmonary eosinophilia and Th2-type cytokine production in an ovalbumin-induced allergic asthma. Down-regulation of TNF-alpha expression in the lung. ( 18068107 )
2008
38
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. ( 17996260 )
2008
39
Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. ( 18094193 )
2008
40
Pulmonary eosinophilia. ( 18197481 )
2008
41
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. ( 18242596 )
2008
42
Tropical pulmonary eosinophilia in a patient undergoing open heart surgery. ( 18285744 )
2008
43
Transient pulmonary eosinophilia incidentally found on low-dose computed tomography: findings in 40 individuals. ( 18303297 )
2008
44
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. ( 18519743 )
2008
45
Pulmonary eosinophilia correlates with allergen deposition to the lower respiratory tract in a mouse model of asthma. ( 18537985 )
2008
46
The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. ( 19017987 )
2008
47
Eosinophilic pustular folliculitis associated with pulmonary eosinophilia. ( 17714146 )
2007
48
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. ( 17079327 )
2007
49
A critical role for Pin1 in allergic pulmonary eosinophilia in rats. ( 17720236 )
2007
50
Tropical pulmonary eosinophilia: a rare cause of cough in immigrants to Australia. ( 17908009 )
2007
Sources

Variations for Pulmonary Eosinophilia

About this section
Sources

Expression for Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.
Sources

Pathways for Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.76 CCL11 CCL5 EPX IL13 IL4 IL5
2
PEDF Induced Signaling 65
Show member pathways
 13.42 CCL11 CCL17 CCL5 IL13 IL4 IL5
3
TGF-Beta Pathway 65
Show member pathways
 13.31 CCL11 CCL17 CCL5 IL13 IL4 IL5
4
Akt Signaling 65
Show member pathways
 13.19 CCL11 CCL17 CCL5 IL13 IL4 IL5
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.12 CCL11 CCL5 IL13 IL4 IL5
6
PAK Pathway 65
Show member pathways
 13.08 CCL11 CCL17 CCL5 IL13 IL4 IL5
7
Allograft rejection 38 1
Show member pathways
 12.67 CCL11 EPX IL13 IL4 IL5 RNASE3
8
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.17 IL13 IL4 IL5
9
IL-17 Family Signaling Pathways 66
Show member pathways
 12.13 CCL11 CCL17 IL13 IL4 IL5
10
Bacterial infections in CF airways 23
Show member pathways
 11.99 CCL11 IL4 SFTPD
11
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 66
Show member pathways
 11.82 CCL11 CCL17 CCL5
12
Interleukin-4 and 13 signaling 67
11.81 CCL11 IL13 IL4
13
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.81 CCL11 CCL17 CCL5 IL13 IL4 IL5
14
Glucocorticoid receptor regulatory network 1
11.65 IL13 IL4 IL5
15
Innate Lymphoid Cell Differentiation Pathways 66
11.63 IL13 IL4 IL5
16
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.51 CCL11 CCL17 CCL5 IL13 IL4
17
IL4-mediated signaling events 1
11.47 CCL11 CCL17 IL4 IL5
18
Interleukin-10 signaling 67
11.39 CCL5 IL13 IL4
19
Development and heterogeneity of the ILC family 1
11.19 IL13 IL4 IL5
20
Lung fibrosis 1
11.15 CCL11 CCL5 IL13 IL4 IL5
21
Inflammatory Response Pathway 1
11.14 IL4 IL5
22
Cytokines and Inflammatory Response 1
11.13 IL13 IL4 IL5
23
OX40 Pathway 65
11.07 IL13 IL4 IL5
24
G-protein signaling_RhoB regulation pathway 23
10.86 CCL11 CCL17 CCL5 IL13 IL4 IL5
25
G-protein signaling_Rap2B regulation pathway 23
10.81 CCL11 CCL17 CCL5 IL13 IL4 IL5
26
Th2 Differentiation Pathway 66
10.68 CCL11 CCL17 IL13 IL4 IL5
Sources

GO Terms for Pulmonary Eosinophilia

About this section

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL11 CCL17 CCL5 EPX IL13 IL4
2 extracellular space GO:0005615 9.28 CCL11 CCL17 CCL5 EPX IL13 IL4

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.78 EPX RNASE3 SFTPD
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 CCL11 CCL17 CCL5
3 chemotaxis GO:0006935 9.74 CCL11 CCL17 CCL5
4 cellular response to tumor necrosis factor GO:0071356 9.73 CCL11 CCL17 CCL5
5 cellular response to interferon-gamma GO:0071346 9.71 CCL11 CCL17 CCL5
6 neutrophil chemotaxis GO:0030593 9.7 CCL11 CCL17 CCL5
7 cellular response to interleukin-1 GO:0071347 9.69 CCL11 CCL17 CCL5
8 chemokine-mediated signaling pathway GO:0070098 9.65 CCL11 CCL17 CCL5
9 inflammatory response GO:0006954 9.65 CCL11 CCL17 CCL5 IL13 IL5
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 CCL5 IL13 IL4
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.59 IL13 IL4
12 positive regulation of JAK-STAT cascade GO:0046427 9.58 CCL5 IL5
13 eosinophil chemotaxis GO:0048245 9.58 CCL11 CCL5
14 monocyte chemotaxis GO:0002548 9.58 CCL11 CCL17 CCL5
15 macrophage chemotaxis GO:0048246 9.55 CCL5 SFTPD
16 cytokine-mediated signaling pathway GO:0019221 9.55 CCL11 CCL5 IL13 IL4 IL5
17 positive regulation of B cell proliferation GO:0030890 9.54 IL13 IL4 IL5
18 lymphocyte chemotaxis GO:0048247 9.5 CCL11 CCL17 CCL5
19 induction of bacterial agglutination GO:0043152 9.49 RNASE3 SFTPD
20 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL13 IL4
21 immune response GO:0006955 9.43 CCL11 CCL17 CCL5 IL13 IL4 IL5
22 regulation of signaling receptor activity GO:0010469 9.1 CCL11 CCL17 CCL5 IL13 IL4 IL5

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL11 CCL17 CCL5
2 lipopolysaccharide binding GO:0001530 9.37 RNASE3 SFTPD
3 cytokine receptor binding GO:0005126 9.32 IL13 IL4
4 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5
5 CCR chemokine receptor binding GO:0048020 9.13 CCL11 CCL17 CCL5
6 cytokine activity GO:0005125 9.1 CCL11 CCL17 CCL5 IL13 IL4 IL5
Sources

Sources for Pulmonary Eosinophilia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....